Ascletis Announces First Participants with Obesity or Overweight Dosed in a U.S. 13-week Phase IIa Study of Small Molecule Oral GLP-1R Agonist ASC30
First participants with obesity or overweight with at least one weight-related comorbidity have been dosed in a U.S. 13-week Phase IIa study of small molecule oral GLP-1receptoragonist ASC30. ASC30 oral once-daily tablet demonstrated up to 6.5% placebo-adjusted meanbody weight reduction from baseline after four-week treatment in a U.S. Phase Ib study. Topline data from ASC30 […]